ramucirumab
Sign in to saveAlso known as IMC-1121B, 1121B
Ramucirumab(), sold under the brand name Cyramza, is a fully human monoclonal antibody (IgG1) used for the treatment of cancer. Ramucirumab is a human vascular endothelial growth factor receptor 2 (VEGFR2) antagonist. Ramucirumab was developed by ImClone Systems.
In the Vinony graph
Within Vinony's link graph, ramucirumab is referenced by 672 other articles, and connects out to tirzepatide, tadalafil and cetuximab.
Vinony files it under Angiogenesis inhibitors, Chemicals that do not have a ChemSpider ID assigned and Drugboxes which contain changes to verified fields.
Its subject is documented across 13 Wikipedia language editions.
Key facts
- Drug.S
- 46
- Drug.Verifiedfields
- changed
- Drug.Watchedfields
- changed
- Drug.verifiedrevid
- 464380023
- Drug.type
- mab
- Drug.mab_type
- mab
- Drug.source
- u
- Drug.target
- VEGFR2 (KDR)
- Drug.tradename
- Cyramza
- Drug.MedlinePlus
- a614026
- Drug.DailyMedID
- Ramucirumab
- Drug.routes_of_administration
- Intravenous infusion
- Drug.class
- Antineoplastic
- Drug.ATC_prefix
- L01
- Drug.ATC_suffix
- FG02
- Drug.legal_AU
- S4
- Drug.legal_CA
- Rx-only
- Drug.legal_US
- Rx-only
via Wikipedia infobox
Chemical data
Drug data · ChEMBL
- Max clinical phase
- Approved
- Molecule type
- Antibody
- First approval
- 2014
- Admin. routes
- parenteral
- Indications
- non-small cell lung carcinoma, gastric carcinoma, neoplasm, hepatocellular carcinoma
via ChEMBL · EBI
Research
1,590 papers- Trastuzumab Deruxtecan or Ramucirumab plus Paclitaxel in Gastric Cancer.The New England journal of medicine · 2025
- Ramucirumab plus docetaxel versus placebo plus docetaxel for second-line treatment of stage IV non-small-cell lung cancer after disease progression on platinum-based therapy (REVEL): a multicentre, double-blind, randomised phase 3 trial.Lancet (London, England) · 2014
- Ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (RAINBOW): a double-blind, randomised phase 3 trial.The Lancet. Oncology · 2014
- Ramucirumab: A Review in Hepatocellular Carcinoma.Drugs · 2020
- Ramucirumab monotherapy for previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (REGARD): an international, randomised, multicentre, placebo-controlled, phase 3 trial.Lancet (London, England) · 2014
via PubMed
Wikidata facts
- Subclass of
- chemical compound
- Has part
- carbon
- Has use
- medication
Show 4 more facts
- medical condition treated
- non-small-cell lung carcinoma
- World Health Organisation international non-proprietary name
- ramucirumab
- subject has role
- monoclonal antibody
- has characteristic
- biopharmaceutical
via Wikidata · CC0
~5 min read
Encyclopedic overview
8 sectionsContents
- Medical uses
- Contraindications
- Side effects
- Pharmacology
- Mechanism of action
- History
- Clinical trials
- References
Ramucirumab(), sold under the brand name Cyramza, is a fully human monoclonal antibody (IgG1) used for the treatment of cancer. Ramucirumab is a human vascular endothelial growth factor receptor 2 (VEGFR2) antagonist. Ramucirumab was developed by ImClone Systems.
== Medical uses == Ramucirumab is indicated for the treatment of gastric cancer, colorectal cancer, non-small cell lung cancer, and hepatocellular carcinoma.
Excerpted from Wikipedia’s “ramucirumab” article, available under the CC BY-SA 4.0 licence.